COVID CLA THIRD AMENDMENT AND RESTATEMENT AGREEMENTCovid Collaboration and License Agreement • April 28th, 2022 • CureVac N.V. • Pharmaceutical preparations
CONTENTS Section Page 1. Interpretation 3 2. Effective Date 3 3. Amendment and Restatement 4 4. Representations and Warranties 4 5. General Provisions 4 Schedule 1. Amended and Restated COVID CLA 7
REDACTED Certain identified information, indicated by [*****], has been excluded from the exhibit because it is both (i) not material and (ii) would likely cause competitive harm if publicly disclosed.Collaboration and License Agreement • April 28th, 2022 • CureVac N.V. • Pharmaceutical preparations
Section Page 1. Interpretation 3 2. Effective Date 4 3. Amendment and Restatement 4 4. Representations and Warranties 4 5. General Provisions 4 Schedule 1. Amended and Restated 2020 CLA 7
SECOND AMENDMENT TO SPONSORED RESEARCH AGREEMENTTo Agreement • April 28th, 2022 • CureVac N.V. • Pharmaceutical preparations
This second amendment to Agreement (the “Second Amendment”), is effective as of July 29, 2021 (“Second Amendment Effective Date”), by and between The Schepens Eye Research Institute, Inc., a not-for-profit Massachusetts corporation, having a principal place of business at 20 Staniford Street, Boston, Massachusetts 02114 (“SERI”), and Massachusetts Eye and Ear Infirmary, having a principal place of business at 243 Charles Street, Boston, Massachusetts 02114 (“MEEI”) (collectively, SERI and MEEI shall be referred to herein as “Hospitals”), and CureVac AG, a German stock corporation, having a principal place of business at Friedrich-Miescher-Straße 15, 72076 Tübingen, Germany (“Sponsor”), each herein referred to as a “Party” and collectively as the “Parties”. Capitalized terms that are not defined herein shall have the meaning ascribed to them in the Agreement (as defined below).
Consultancy AgreementConsultancy Agreement • April 28th, 2022 • CureVac N.V. • Pharmaceutical preparations
Route de Renipont 25c, 1380 Ohain, Belgium; registered under number BE 0740.928.560, and duly represented by its Managing Director, Antony Blanc
1st Amendment to the Consultancy Agreement between CureVac AG Friedrich- Miescher-Str. 15, 72076 Tübingen, Germany - hereinafter referred to as “CureVac” - and Clarentis SRL Route de Renipont 25c, 1380 Ohain, Belgium; registered under number BE...Consultancy Agreement • April 28th, 2022 • CureVac N.V. • Pharmaceutical preparations
This amendment shall enter into force upon signature. The remaining terms and conditions of the Agreement remain in force unamended. All capitalized terms used herein shall have the same meaning as defined in the Agreement, unless expressly stated otherwise.
REDACTED Certain identified information, indicated by [*****], has been excluded from the exhibit because it is both (i) not material and (ii) would likely cause competitive harm if publicly disclosed. THIRD AMENDMENT TO COLLABORATION AND LICENSE...Collaboration and License Agreement • April 28th, 2022 • CureVac N.V. • Pharmaceutical preparations
This THIRD AMENDMENT TO COLLABORATION AND LICENSE AGREEMENT (“Third Amendment”) is effective as of the 30th day of June 2021 (“Third Amendment Effective Date”), by and between:
THIRD AMENDMENT TO SPONSORED RESEARCH AGREEMENTSponsored Research Agreement • April 28th, 2022 • CureVac N.V. • Pharmaceutical preparations
This third amendment to Agreement (the “Third Amendment”), is effective as of September 1, 2021 (“Third Amendment Effective Date”), by and between The Schepens Eye Research Institute, Inc., a not-for-profit Massachusetts corporation, having a principal place of business at 20 Staniford Street, Boston, Massachusetts 02114 (“SERI”), and Massachusetts Eye and Ear Infirmary, having a principal place of business at 243 Charles Street, Boston, Massachusetts 02114 (“MEEI”) (collectively, SERI and MEEI shall be referred to herein as “Hospitals”), and CureVac AG, a German stock corporation, having a principal place of business at Friedrich-Miescher-Straße 15, 72076 Tübingen, Germany (“Sponsor”), each herein referred to as a “Party” and collectively as the “Parties”. Capitalized terms that are not defined herein shall have the meaning ascribed to them in the Agreement (as defined below).
CONSORTIUM AGREEMENTConsortium Agreement • April 28th, 2022 • CureVac N.V. • Pharmaceutical preparations
NOW, THEREFORE, in consideration of the premises above and the following mutual covenants and other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the Parties hereby agree as follows:
AMENDMENT NO. 1 TO THE COLLABORATIVE RESEARCH AGREEMENT BETWEEN CureVac AG AND YALE UNIVERSITYCollaborative Research Agreement • April 28th, 2022 • CureVac N.V. • Pharmaceutical preparations
THIS AMENDMENT NO. 1 to the Collaborative Research Agreement (hereinafter “Agreement”) is made effective this 28th day of June, 2021 (hereinafter “Amendment NO. 1 Effective Date”), by and between CureVac AG, a German stock corporation with offices at Friedrich-Miescher-Strasse 15, 72076 Tuebingen, Germany, and Yale University, a non-profit corporation, organized and existing under the and by virtue of a special charter granted by the General Assembly of the Colony and State of Connecticut (hereinafter “Yale”) with an office at 25 Science Park, 150 Munson Street, 3rd Floor, P.O. Box 208327, New Haven, CT 06520-8327.
